BioPharma Resources

Drug Trial Radar · NCT05439629

Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration

A Multicenter, Randomized, Double-blind Phase III Clinical Study Comparing the Efficacy and Safety of BAT5906 and Ranibizumab (Lucentis®) in Patients With Neovascular Age-related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: Dec 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 488 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

488

Actual

Start

Jul 7, 2022

Primary completion

Apr 22, 2025

Study completion Apr 22, 2025

Sponsor

Lead sponsor
Bio-Thera SolutionsIndustry
Sponsor type
Industry
First posted
Jun 30, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A non-inferiority design was used to conduct a randomized, double-blind, parallel-controlled multi-center study. A total of 488 subjects with neovascular (wet) age-related macular degeneration (w-AMD) were planned to be enrolled. Qualified subjects were divided into experimental group and control group in a 1:1 ratio, and stratified randomized according to the letter value of baseline period and whether the eyes had received anti-VEGF drug treatment. The experimental group received BAT5906 injection. The control group received Lucentis® treatment. Only 1 eye per subject was included in this study.

Conditions

  • Neovascular (Wet) Age-related Macular Degeneration

Interventions

  • BAT5906 injectionDrug

    4.0 mg/eye/time, 50 μl, intravitreal injection

  • LucentisDrug

    0.5 mg/eye/time, 50 μl, intravitreal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The change in the BCVA valueTime frame: Week 52
  2. The change in the BCVA valueTime frame: at weeks 12, 24, 36, and 48
  3. BCVA increased the proportion of subjects with >10, >15, ≥30 wordsTime frame: in the 24th and 52nd weeks
  4. BCVA reduced the proportion of subjects < 10, < 15 wordsTime frame: at weeks 24 and 52
  5. Changes in the thickness of the macular fovea (CRT).Time frame: at weeks 12, 24, 36, 48, and 52

Locations

48 sites in 1 country. Site status is shown where the registry gives one.

  • Affiliated Hospital of Inner Mongolia Medical University

    Beijing, China

  • Beijing Chao Yang Hospital

    Beijing, China

  • Beijing Hospital

    Beijing, China

  • China-Japan Friendship Hospital

    Beijing, China

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

    Beijing, China

  • Peking University People's Hospital

    Beijing, China

  • Xiangya Hospital of Central South University

    Changsha, China

  • The First Affiliated Hospital of Army Medical University (Southwest Hospital)

    Chongqing, China

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, China

  • First Affiliated Hospital of Fujian Medical University

    Fujian, China

  • First Affiliated Hospital, Sun Yat-Sen University

    Guangzhou, China

  • Guangzhou Aier Eye Hospital

    Guangzhou, China

  • Sun Yat-sen Ophthalmic Center, Sun Yat-sen University

    Guangzhou, China

  • The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine

    Guangzhou, China

  • Affiliated Hospital of Guizhou Medical University

    Guiyang, China

  • Zhejiang Provincial People's Hospital

    Hangzhou, China

  • The Second Hospital of Anhui Medical University

    Hefei, China

  • People's Hospital of Wuhan University (Hubei Provincial People's Hospital)

    Hubei, China

  • The First Hospital of Jilin University

    Jilin City, China

  • Jinan Second People's Hospital

    Jinan, China

  • The Affiliated Eye Hospital of Shandong University of Chinese Medicine

    Jinan, China

  • Jinzhong First People's Hospital

    Jinzhong, China

  • The First People's Hospital of Kunming

    Kunming, China

  • Luoyang Third People's Hospital

    Luoyang, China

  • The Affiliated Eye Hospital of Nanchang University

    Nanchang, China

  • Jiangsu Provincial Hospital of Traditional Chinese Medicine

    Nanjing, China

  • Affiliated Hospital of Nantong University

    Nantong, China

  • Ningbo Eye Hospital

    Ningbo, China

  • Pingxiang People's Hospital

    Pingxiang, China

  • People's Hospital of Quzhou

    Quzhou, China

  • Huashan Hospital

    Shanghai, China

  • Shanghai Oriental Hospital

    Shanghai, China

  • Shanghai University of Traditional Chinese Medicine

    Shanghai, China

  • The Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, China

  • Shantou University-Chinese University of Hong Kong Joint Shantou International Eye Centre

    Shantou, China

  • The Fourth People's Hospital of Shenyang

    Shenyang, China

  • Shenzhen People's Hospital

    Shenzhen, China

  • Second Hospital of Shanxi Medical University

    Taiyuan, China

  • Taizhou Hospital of Zhejiang Province

    Taizhou, China

  • Weifang Eye Hospital

    Weifang, China

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.